Egetis Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:PDPH.F Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
26 Nov 25	BuyUS$114,640	Mats Blom	Individual	215,000	US$0.55
15 Jul 25	BuyUS$19,392	Yilmaz Mahshid	Individual	35,000	US$0.55
05 Jun 25	BuyUS$6,396	Nicklas Westerholm	Individual	15,100	US$0.42
05 Jun 25	BuyUS$5,702	Laetitia Szaller	Individual	13,460	US$0.42
02 Jun 25	BuyUS$10,774	Henrik Krook	Individual	30,000	US$0.36

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PDPH.F?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	45,069,277	9.76%
Private Companies	61,976,211	13.4%
VC/PE Firms	65,671,105	14.2%
Institutions	117,819,591	25.5%
General Public	171,293,155	37.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.6%.

Top Shareholders

Top 25 shareholders own 62.81% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
14.2%	Frazier Life Sciences Management, LP	65,671,105	US$47.0m	0%	1.22%
8.63%	Peter Lindell	39,847,198	US$28.5m	0%	no data
7.31%	Cetoros AB	33,776,221	US$24.1m	0%	no data
6.13%	Fourth Swedish National Pension Fund (AP4)	28,320,780	US$20.2m	0%	0.07%
3.83%	Avla Holding AB	17,668,330	US$12.6m	0%	no data
3.56%	The Invus Group, LLC	16,428,439	US$11.7m	0%	27.34%
2.99%	Unionen	13,800,000	US$9.9m	0%	3.47%
2.44%	Avanza Fonder AB	11,250,130	US$8.0m	0%	0.07%
2.28%	Recipharm AB	10,531,660	US$7.5m	0%	no data
1.75%	Linc AB	8,074,914	US$5.8m	0%	2.53%
1.31%	Handelsbanken Asset Management	6,065,409	US$4.3m	0%	0.01%
1.27%	Woodline Partners LP	5,850,065	US$4.2m	0%	0.01%
1.17%	Swedbank Robur Fonder AB	5,400,000	US$3.9m	0%	no data
1.06%	Flerie AB (publ)	4,885,231	US$3.5m	0%	7.98%
1.02%	Nordnet AB (publ)	4,723,065	US$3.4m	0%	0.29%
0.89%	BMO Asset Management Corp.	4,108,648	US$2.9m	0%	no data
0.73%	Promepar Asset Management	3,362,851	US$2.4m	0%	17.03%
0.73%	Mats Blom	3,349,762	US$2.4m	-4.29%	no data
0.71%	Healthinvest Partners AB	3,272,688	US$2.3m	0%	0.77%
0.36%	SEB Funds AB	1,682,563	US$1.2m	0%	no data
0.11%	Financiere Arbevel	520,000	US$371.8k	0%	0.09%
0.11%	Nicklas Westerholm	501,511	US$358.5k	94.5%	no data
0.1%	Henrik Krook	459,593	US$328.6k	0%	no data
0.066%	Yilmaz Mahshid	306,249	US$218.9k	57.1%	no data
0.048%	Christian Sonesson	223,250	US$159.6k	90.3%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/21 20:08
End of Day Share Price	2026/04/28 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Egetis Therapeutics AB (publ) is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Patrick Langstrom	ABG Sundal Collier Sponsored
Erik Hultgård	Carnegie Investment Bank AB
Ulrik Trattner	Carnegie Investment Bank AB